Inhibition of endothelial cell proliferation as a potential therapeutic approach in hereditary hemorrhagic telangectasia

Abstract

Arteriovenous malformations are the hallmark of patients with hereditary hemorrhagic telangectasia. Research now finds that this could be due to endothelial cell-cycle acceleration via CDK6. These results could suggest repurposing CDK6 inhibitors for this disorder.